Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamir Shragai

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancers|February 27, 2026
Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable OutcomesGil Fridberg, Inbar Cohen, Renana Robinson, et al.
European Journal of Haematology|October 22, 2020
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature reviewTamir Shragai, Moshe Gatt, Noa Lavie, et al.
Haematologica|February 12, 2026
ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot studyGil Fridberg, Odelia Amit, Yehonathan Sherf, et al.
Hematological Oncology|April 7, 2026
The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non-Secretory Relapse-A Retrospective Cohort StudyIuliana Vaxman, Itai Zamir, Inbar Cohen, et al.
Leukemia Research|January 16, 2021
Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre studyTamir Shragai, Moshe E Gatt, Adir Shaulov, et al.
British Journal of Haematology|July 1, 2021
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myelomaIrit Avivi, Roi Balaban, Tamir Shragai, et al.
British Journal of Haematology|October 7, 2022
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective studyTamir Shragai, Hila Magen, Noa Lavi, et al.
American Journal of Hematology|July 24, 2019
Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patientsIrit Avivi, Yael C Cohen, Anna Suska, et al.
Transplantation and Cellular Therapy|October 13, 2024
Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional StudyRon Ram, Odelia Amit, Chava Perry, et al.
Haematologica|March 5, 2026
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trialsKatarina Uttervall, Martin K Kortum, Aurore Perrot, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancers|February 27, 2026
Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable OutcomesGil Fridberg, Inbar Cohen, Renana Robinson, et al.
European Journal of Haematology|October 22, 2020
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature reviewTamir Shragai, Moshe Gatt, Noa Lavie, et al.
Haematologica|February 12, 2026
ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot studyGil Fridberg, Odelia Amit, Yehonathan Sherf, et al.
Hematological Oncology|April 7, 2026
The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non-Secretory Relapse-A Retrospective Cohort StudyIuliana Vaxman, Itai Zamir, Inbar Cohen, et al.
Leukemia Research|January 16, 2021
Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre studyTamir Shragai, Moshe E Gatt, Adir Shaulov, et al.
British Journal of Haematology|July 1, 2021
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myelomaIrit Avivi, Roi Balaban, Tamir Shragai, et al.
British Journal of Haematology|October 7, 2022
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective studyTamir Shragai, Hila Magen, Noa Lavi, et al.
American Journal of Hematology|July 24, 2019
Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patientsIrit Avivi, Yael C Cohen, Anna Suska, et al.
Transplantation and Cellular Therapy|October 13, 2024
Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional StudyRon Ram, Odelia Amit, Chava Perry, et al.
Haematologica|March 5, 2026
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trialsKatarina Uttervall, Martin K Kortum, Aurore Perrot, et al.
Pageof 2